Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2025CancersOpen Access

Management of Triple M Syndrome: A Narrative Review of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis, Myositis and Myocarditis

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMartin FurlepaIWIsabella WattsImperial College Healthcare NHS TrustACAisling CarrUniversity College London

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Furlepa et al. (2025) studied this question.

synapsesocial.com/papers/6a6ff31b31a3df8243283dfehttps://doi.org/10.3390/cancers17132063
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up2017 · 2,383 citations
  2. 2Rituximab treatment in myasthenia gravis2023 · 47 citations
  3. 3Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action2024 · 14 citations
  4. 4Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma2025 · 12 citations
  5. 5Immune Checkpoint Inhibitor Myopathy2024 · 32 citations